Consensus EPS · Q3 2026
$4.66
Consensus revenue · Q3 2026
$49.1B
Analysts
17
Expected report
Oct 21, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 17 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $48.4B | $49.1B | $50.2B |
| EPS | $4.55 | $4.66 | $4.99 |
| EBITDA | $2.9B | $3B | $3.1B |
| EBIT | $2.5B | $2.6B | $2.7B |
| Net income | $948.5M | $1B | $1.3B |
- Revenue$49.1B
- EPS$4.66
- EBITDA$3B
- EBIT$2.6B
- Net income$1B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q2 2026 | $49.8B | $48.9B | +1.9% | $7.45 | $6.21 | +19.9% |
| Q1 2026 | $49.5B | $48.2B | +2.7% | $12.58 | $10.82 | +16.3% |
| Q4 2025 | $49.3B | $49.8B | -1.1% | $3.33 | $3.10 | +7.5% |
- Q2 2026+1.9%+19.9%
- Q1 2026+2.7%+16.3%
- Q4 2025-1.1%+7.5%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Elevance Health (ELV) Q3 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 14 analysts.
- Low
- $391.00
- Consensus
- $440.17
- Median
- $452.50
- High
- $498.00
- Current
- $377.68
- Upside
- +16.5%
Upside calculated vs most recent trading price of $377.68.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 38 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 2026 | Leerink Partners | maintain | Market Perform | Market Perform |
| Jul 16, 2026 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 16, 2026 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Jul 16, 2026 | Guggenheim | maintain | Buy | Buy |
| Jul 16, 2026 | Barclays | maintain | Overweight | Overweight |
| Jul 16, 2026 | Baird | maintain | Neutral | Neutral |
| Jul 14, 2026 | Truist Securities | maintain | Buy | Buy |
| Jul 14, 2026 | TD Cowen | maintain | Buy | Buy |
| Jul 13, 2026 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 9, 2026 | RBC Capital | maintain | Sector Perform | Sector Perform |
- Jul 17, 2026Leerink PartnersMarket Perform
- Jul 16, 2026Wells FargoOverweight
- Jul 16, 2026RBC CapitalSector Perform
- Jul 16, 2026GuggenheimBuy
- Jul 16, 2026BarclaysOverweight
- Jul 16, 2026BairdNeutral
- Jul 14, 2026Truist SecuritiesBuy
- Jul 14, 2026TD CowenBuy
- Jul 13, 2026Wells FargoOverweight
- Jul 9, 2026RBC CapitalSector Perform
Frequently asked questions
Elevance Health (ELV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks3.21% TTM
- Dividend Profile1.82% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History1 split
How this company returns cash to shareholders — buybacks, dividends, and stock splits.